Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies

October 3, 2022

Oct. 3, EMERYVILLE, Calif. – Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR gene editing tools, today announced its participation in the following investor and industry conferences:

Chardan’s 6th Annual Genetic Medicines Conference – New York City
Corporate presentation, 9:00 – 9:25 a.m. EDT, followed by a panel presentation on next-generation gene editing, 9:30 – 10:15 a.m. EDT, on October 3
1×1 meetings with institutional investors
Participants: Brian C. Thomas, Ph.D., CEO and founder, and Simon Harnest, CIO, SVP Strategy

BMO BioPharma Spotlight Series – Gene Editing & Therapy
Panel presentation titled “Discovery Of Unique Gene Editing Systems And Application In Therapeutics” on October 6, 12:00 p.m. EDT
Participant: Simon Harnest, CIO, SVP Strategy

Truist Securities Genetic Medicine Summit
October 20
Participant: Simon Harnest, CIO, SVP Strategy

5th International Conference on CRISPR Technologies
Two scientific presentations, October 31 – November 2
Participants: Chris Brown, Ph.D., Director of Discovery, and Cindy Castelle, Ph.D., Associate Director, Functional Assay Development & Screening

About Metagenomi
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit


Investor Contact:
Simon Harnest, CIO, SVP Strategy
+1 (917) 403-1051

Media Contact:
Ashlye Hodge
+1 (510) 734-4409